Race Oncology announced the appointment of Dr. Michelle Rashford as Chief Medical Officer (CMO), taking over from Interim CMO, Dr. Ajay Duggal. Dr. Rashford is an internationally experienced biopharmaceutical executive and former physician, with expertise in the successful development and commercialisation of pharmaceuticals across oncology, virology, and immunology. Her 25+ years of drug development experience spans large pharmaceuticals to smaller biotech companies and includes pre-clinical and clinical development, medical and regulatory affairs, and drug commercialisation.

Dr. Rashford will join Race Oncology on 1 July 2023 from the Japanese Pharmaceutical company Kyowa Kirin, where she has been the Head of Global Clinical Sciences. Prior to her role at Kyowa Kirin, Dr. Rashford was the Senior Vice President of Clinical Science at Adlai Nortye Biopharma, where she successfully grew the US Clinical Development team and prepared for the company's Phase III trial. She has also held senior roles within global pharmaceutical companies, including five years at Bristol-Myers Squibb and close to 20 years at Roche in a variety of national and global clinical development roles.

Dr. Rashford holds a Bachelor of Medicine & Bachelor of Surgery from the University of Tasmania, Australia.